| UNITED STATES | |
| SECURITIES AND EXCHANGE COMMISSION | |
| Washington, D.C. 20549 | |
| Notice of Effectiveness | |
| Effectiveness Date: | April 15, 2025 4:30 P.M. |
| Form: | S-3 | ||||||
| |||||||
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/20/2025 | Outperform | William Blair | |
| 5/27/2025 | $5.00 | Neutral → Buy | H.C. Wainwright |
| 10/10/2024 | $13.00 | Buy | UBS |
| 10/9/2024 | $16.00 | Buy | Rodman & Renshaw |
| 7/3/2024 | $8.00 | Neutral | H.C. Wainwright |
| 3/4/2024 | $40.00 | Overweight | Morgan Stanley |
| 3/4/2024 | $39.00 | Overweight | JP Morgan |
| 3/4/2024 | $44.00 | Overweight | Wells Fargo |
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
SCHEDULE 13G/A - Kyverna Therapeutics, Inc. (0001994702) (Subject)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
8-K - Kyverna Therapeutics, Inc. (0001994702) (Filer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
4 - Kyverna Therapeutics, Inc. (0001994702) (Issuer)
EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is
Advancing valuable commercial opportunity in stiff person syndrome (SPS) following landmark registrational data; Biologics License Application (BLA) submission anticipated in 1H 2026 First patient enrolled in registrational Phase 3 trial in generalized myasthenia gravis (gMG) Completed follow-on offering extends cash runway into 2028, expected to fully fund SPS BLA filing, commercial launch, and Phase 3 gMG trial Kyverna Board member, Christi Shaw, appointed as Executive Chairperson, further bolstering Company's CAR T commercialization experience; Ian Clark, former Chairperson, to remain on Board EMERYVILLE, Calif., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyver
EMERYVILLE, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that Warner Biddle, Chief Executive Officer of Kyverna, will present at the J.P. Morgan 2026 Healthcare Conference in San Francisco on Wednesday, January 14th, 2026, at 9:45 a.m. PT. A live audio webcast of the presentation may be accessed via the Investors section of the Kyverna website at ir.kyvernatx.com. A replay of the webcast will be available on the website for 30 days following the conference. About Kyverna TherapeuticsKyverna Therapeutics, In
William Blair initiated coverage of Kyverna Therapeutics with a rating of Outperform
H.C. Wainwright upgraded Kyverna Therapeutics from Neutral to Buy and set a new price target of $5.00
UBS initiated coverage of Kyverna Therapeutics with a rating of Buy and set a new price target of $13.00
EMERYVILLE, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical stage biopharmaceutical company developing cell therapies for patients with autoimmune diseases, today announced the appointment of Mayo Pujols as its Chief Technology Officer (CTO), effective February 9, 2026. Mr. Pujols brings more than 30 years of technical operations experience to the role with a deep background in leading late-stage and commercial manufacturing for cell and gene therapies. His work spans both large-scale and smaller biopharmaceutical companies with a proven track record of successfully advancing programs across their lifecycles. He succeeds Karen Walker, who is
Topline data for registrational Phase 2 trial of KYV-101 in stiff person syndrome (SPS) andBLA submission anticipated in 1H 2026 Registrational Phase 3 KYV-101 trial in myasthenia gravis (MG) to include ~60 patients with enrollment to initiate by year-end 2025; interim Phase 2 data expected in Q4 2025 Strong cash position to support upcoming milestones EMERYVILLE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today reported its business highlights and financial results for the quarter ended June 30, 2025. "The second quarter was
Webcast to be held August 28, 2025, 11:00am ET EMERYVILLE, Calif., July 29, 2025 /PRNewswire/ -- Kyverna Therapeutics, Inc. ((Kyverna, NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced that the Company will host a webcast event with Key Opinion Leaders (KOLs) to discuss its neuroimmunology franchise. The event will take place on Thursday, August 28, 2025, from 11:00am to 1:30pm ET. Presentations will feature members of the Company's management team and the following renowned KOLs: Srikanth Muppidi, M.D., Stanford MedicineRicardo Grieshaber-Bouyer, M.D., Ph.D., FAU Erlangen-NümbergAiden Haghiki
Landmark results could pave the way for miv-cel to become the first FDA-approved CAR T-cell therapy for autoimmune disease; Company on track to submit BLA for stiff person syndrome in 1H 2026 Miv-cel achieved statistically significant clinical benefit across all primary and secondary endpoints, reversing disability and eliminating immunotherapies after a single dose Miv-cel was generally well-tolerated with no high-grade CRS or ICANS observed SPS is a debilitating, progressive autoimmune disease with no FDA-approved therapies Company to host webcast today, December 15, 2025 at 8 am ET EMERYVILLE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a c
EMERYVILLE, Calif., Dec. 14, 2025 (GLOBE NEWSWIRE) -- Kyverna Therapeutics, Inc. (NASDAQ:KYTX), a clinical-stage biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, announced it will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 am ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS). Conference Call Details Participants will need to register at the below-noted URL in order to listen and participate in the call. Once registered, participants will receive a dial-in phone number and unique PIN number which will be needed to join th
Compelling results set new clinical standard in generalized myasthenia gravis (gMG), increasing confidence in the Company's registrational KYSA-6 Phase 3 MG trial 100% of patients achieved clinically meaningful responses in MG-ADL and QMG -- the co-primary endpoints of the Phase 3 trial -- with mean reductions of -8.0 pts and -7.7 points at 24 weeks KYV-101 was well-tolerated with no high-grade CRS and no ICANS observed, further supporting the consistent and manageable safety profile of KYV-101 Unprecedented results further reinforce KYV-101's potential to deliver durable, drug-free, disease-free remission with a single dose Company to host conference call today, October 29, 2025, at 8:0
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13G - Kyverna Therapeutics, Inc. (0001994702) (Subject)
SC 13D - Kyverna Therapeutics, Inc. (0001994702) (Subject)